{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:24:27Z","timestamp":1789709067662,"version":"4.0.1"},"reference-count":248,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chemotherapy resistance and peculiar tumor microenvironment, which diminish or mitigate the effects of therapies, make pancreatic cancer one of the deadliest malignancies to manage and treat. Advanced immunotherapies are under consideration intending to ameliorate the overall patient survival rate in pancreatic cancer. Oncolytic viruses therapy is a new type of immunotherapy in which a virus after infecting and lysis the cancer cell induces\/activates patients\u2019 immune response by releasing tumor antigen in the blood. The current review covers the pathways and molecular ablation that take place in pancreatic cancer cells. It also unfolds the extensive preclinical and clinical trial studies of oncolytic viruses performed and\/or undergoing to design an efficacious therapy against pancreatic cancer.<\/jats:p>","DOI":"10.3389\/fonc.2022.875188","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T10:53:05Z","timestamp":1653389585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Maryum","family":"Nisar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan Zafar","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumair Naseem","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussnain Ahmed","family":"Janjua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","article-title":"Addressing the Challenges of Pancreatic Cancer: Future Directions for Improving Outcomes","volume":"15","author":"Hidalgo","year":"2015","journal-title":"Pancreatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting Cancer Incidence and Deaths to 2030: The Unexpected","volume":"74","author":"Rahib Smith","year":"2014","journal-title":"Cancer Res"},{"key":"B4","article-title":"Diagnosis and Management of Pancreatic Cancer","volume":"89","author":"De La Cruz","year":"2014","journal-title":"Am Fam Physician"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.21717","article-title":"Looking to Long-Term Survivors for Improved Pancreatic Cancer Treatment","volume":"324","author":"Kuehn","year":"2020","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic Pancreatic Cancer: Asco Guideline Update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic Cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.04.001","article-title":"Gemcitabine in the Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Meta-Analysis","volume":"99","author":"Zhu","year":"2011","journal-title":"Radiotherapy Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 Multi-Institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox Versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.3390\/cancers13164138","article-title":"Pancreatic Cancer and Immunotherapy: A Clinical Overview","volume":"13","author":"Timmer","year":"2021","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.7150\/jca.14922","article-title":"Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment","volume":"7","author":"Polireddy","year":"2016","journal-title":"J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer Stem Cells\u2014Origins and Biomarkers: Perspectives for Targeted Personalized Therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2646148","DOI":"10.1155\/2017\/2646148","article-title":"Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review","volume":"2017","author":"Wang","year":"2017","journal-title":"BioMed Res Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.646399","article-title":"Epithelial-Mesenchymal Transition and Its Regulation Mechanisms in Pancreatic Cancer","volume":"11","author":"Luu","year":"2021","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers10020052","article-title":"Epithelial-Mesenchymal Transition in Cancer: An Overview","volume":"4","author":"Ramos","year":"2017","journal-title":"Integr Cancer Sci Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging Biological Principles of Metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164368","article-title":"Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole Genomes Redefine the Mutational Landscape of Pancreatic Cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/19336918.2015.1016686","article-title":"A New Role for the Pi3k\/Akt Signaling Pathway in the Epithelial-Mesenchymal Transition","volume":"9","author":"Xu","year":"2015","journal-title":"Cell Adhesion Migration"},{"key":"B22","doi-asserted-by":"publisher","first-page":"289243","DOI":"10.1155\/2012\/289243","article-title":"The Roles of Mitogen-Activated Protein Kinase Pathways in Tgf-\u03b2-Induced Epithelial-Mesenchymal Transition","volume":"2012","author":"Gui","year":"2012","journal-title":"J Signal Transduction 2012"},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cac2.12138","article-title":"Emt-Associated Micrornas and Their Roles in Cancer Stemness and Drug Resistance","volume":"41","author":"Pan","year":"2021","journal-title":"Cancer Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/1878-0261.12096","article-title":"Revisiting Epithelial-Mesenchymal Transition in Cancer Metastasis: The Connection Between Epithelial Plasticity and Stemness","volume":"11","author":"Liao","year":"2017","journal-title":"Mol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29664","article-title":"Identification of Germline Genetic Mutations in Patients With Pancreatic Cancer","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic Cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1644","article-title":"Microrna Biogenesis: Coordinated Cropping and Dicing","volume":"6","author":"Kim","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2014.09.006","article-title":"Mirnas in Pancreatic Cancer: Therapeutic Potential, Delivery Challenges and Strategies","volume":"81","author":"Chitkara","year":"2015","journal-title":"Advanced Drug Deliv Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3892\/ijo.2019.4676","article-title":"Microrna-200b and-301 Are Associated With Gemcitabine Response as Biomarkers in Pancreatic Carcinoma Cells","volume":"54","author":"Funamizu","year":"2019","journal-title":"Int J Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2011.03.012","article-title":"Retracted: Notch-1 Induces Epithe865 Lial\u2013Mesenchymal Transition Consistent With Cancer Stem Cell Phenotype in Pancreatic Cancer Cells","volume":"307","author":"Bao","year":"2011","journal-title":"Cancer Lett"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-04191-w","article-title":"Mir-509-5p and Mir-1243 Increase the Sensitivity to Gemcitabine by Inhibiting Epithelial-Mesenchymal Transition in Pancreatic Cancer","volume":"7","author":"Hiramoto","year":"2017","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404396","article-title":"Zeb 1-Associated Drug Resistance in Cancer Cells Is Reversed by the Class I Hdac Inhibitor Mocetinostat","volume":"7","author":"Meidhof","year":"2015","journal-title":"EMBO Mol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.06.114","article-title":"Mir-125a-3p Is Responsible for Chemosensitivity in Pdac by Inhibiting Epithelial-Mesenchymal Transition via Fyn","volume":"106","author":"Liu","year":"2018","journal-title":"Biomedicine Pharmacother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1115-2","article-title":"Mir-148a Regulates the Growth and Apoptosis in Pancreatic Cancer by Targeting Cckbr and Bcl-2","volume":"35","author":"Zhang","year":"2014","journal-title":"Tumor Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210228","article-title":"Microrna Expression Alterations Are Linked to Tumorigenesis and Non-Neoplastic Processes in Pancreatic Ductal Adenocarcinoma","volume":"26","author":"Szafranska","year":"2007","journal-title":"Oncogene"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2013.02.009","article-title":"Network, Nodes and Nexus: Systems Approach to Multitarget Therapeutics","volume":"24","author":"Murthy","year":"2013","journal-title":"Curr Opin Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nmeth.3440","article-title":"Pathway and Network Analysis of Cancer Genomes","volume":"12","author":"Creixell","year":"2015","journal-title":"Nat Methods"},{"key":"B38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00428-019-02532-w","article-title":"Role of Epithelial\u2013Mesenchymal Transition Factors in the Histogenesis of Uterine Carcinomas","volume":"475","author":"Franceschi","year":"2019","journal-title":"Virchows Archiv"},{"key":"B39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New Insights Into the Mechanisms of Epithelial\u2013Mesenchymal Transition and Implications for Cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.11.025","article-title":"Emt and Dissemination Precede Pancreatic Tumor Formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-Mesenchymal Transitions in Development and Disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"150960","DOI":"10.1155\/2010\/150960","article-title":"Clinical Relevance of Kras in Human Cancers","volume":"2010","author":"Jan\u010d\u00edk","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1146\/annurev.bi.56.070187.004023","article-title":"Ras Genes","volume":"56","author":"Barbacid","year":"1987","journal-title":"Ann Rev Biochem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1289\/ehp.929813","article-title":"Role of Proto-Oncogene Activation in Carcinogenesis","volume":"98","author":"Anderson","year":"1992","journal-title":"Environ Health Perspect"},{"key":"B45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1383-5718(01)00291-1","article-title":"Dna Adducts, Genetic Polymorphisms, and K-Ras Mutation in Human Pancreatic Cancer","volume":"513","author":"Li","year":"2002","journal-title":"Mutat Research\/Genetic Toxicol Environ Mutagenesis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","article-title":"Kras: The Critical Driver and Therapeutic Target for Pancreatic Cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09990-2","article-title":"Targeting Kras in Pancreatic Cancer: New Drugs on the Horizon","volume":"40","author":"Bannoura","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09914-6","article-title":"Structure-Based Inhibitor Design of Mutant Ras Proteins\u2014A Paradigm Shift","volume":"39","author":"Ny\u00edri","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00335","article-title":"Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics","volume":"9","author":"Murthy","year":"2018","journal-title":"Front Physiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/ijms23031309","article-title":"Identification of New Kras G12d Inhibitors Through Computer-Aided Drug Discovery Methods","volume":"23","author":"Kulkarni","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00195-5","article-title":"Cracking Kras","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.3390\/cancers13174434","article-title":"Targeting Pi3k Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress","volume":"13","author":"Mehra","year":"2021","journal-title":"Cancers"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5200","article-title":"Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer","volume":"68","author":"Jimeno","year":"2008","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.01.023","article-title":"Selective Requirement of Pi3k\/Pdk1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer","volume":"23","author":"Eser","year":"2013","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1151","article-title":"Muc1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer","volume":"23","author":"Gunda","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.16","article-title":"Muc1 Induces Drug Resistance in Pancreatic Cancer Cells via Upregulation of Multidrug Resistance Genes","volume":"2","author":"Nath","year":"2013","journal-title":"Oncogenesis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","article-title":"Pathological Roles of Mapk Signaling Pathways in Human Diseases","volume":"1802","author":"Kim","year":"2010","journal-title":"Biochim Biophys Acta (BBA)-Molecular Basis Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2006.8.1775","article-title":"Reactive Oxygen Species-Induced Activation of the Map Kinase Signaling Pathways","volume":"8","author":"McCubrey","year":"2006","journal-title":"Antioxidants Redox Signaling"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210421","article-title":"Map Kinase Signalling Pathways in Cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.09.026","article-title":"Paf-Mediated Mapk Signaling Hyperactivation via Lamtor3 Induces Pancreatic Tumorigenesis","volume":"5","author":"Jun","year":"2013","journal-title":"Cell Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00023","article-title":"Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer","volume":"5","author":"Furukawa","year":"2015","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25496","article-title":"Tgf-\u03b2 Signaling in Cancer","volume":"117","author":"Syed","year":"2016","journal-title":"J Cell Biochem"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-017-0168-0","article-title":"Tgf-\u03b2 in Pancreatic Cancer Initiation and Progression: Two Sides of the Same Coin","volume":"7","author":"Shen","year":"2017","journal-title":"Cell Bioscience"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00605","article-title":"On-Target Anti-Tgf-\u03b2 Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges","volume":"8","author":"Teixeira","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2853","article-title":"Tgf\u03b2 Signalling: A Complex Web in Cancer Progression","volume":"10","author":"Ikushima","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.19.4.709","article-title":"Tgf-\u03b21 Promotes Liver Metastasis of Pancreatic Cancer by Modulating the Capacity of Cellular Invasion","volume":"19","author":"Teraoka","year":"2001","journal-title":"Int J Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-5-98","article-title":"Expression of Transforming Growth Factor-Beta-1 and P27 Kip1 in Pancreatic Adenocarcinomas: Relation With Cell-Cycle-Associated Proteins and Clinicopathologic Characteristics","volume":"5","author":"Culhaci","year":"2005","journal-title":"BMC Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-199911000-00008","article-title":"Enhanced Expression of the Type Ii Transforming Growth Factor-Beta Receptor Is Associated With Decreased Survival in Human Pancreatic Cancer","volume":"19","author":"Wagner","year":"1999","journal-title":"Pancreas"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)91084-U","article-title":"Enhanced Expression of Transforming Growth Factor \u03b2 Isoforms in Pancreatic Cancer Correlates With Decreased Survival","volume":"105","author":"Friess","year":"1993","journal-title":"Gastroenterology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1159\/000108959","article-title":"Basics of Tgf-\u03b2 and Pancreatic Cancer","volume":"7","author":"Truty","year":"2007","journal-title":"Pancreatology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-017-0175-0","article-title":"The Role of Tgf-\u03b2 and its Crosstalk With Rac1\/Rac1b Signaling in Breast and Pancreas Carcinoma","volume":"15","author":"Melzer","year":"2017","journal-title":"Cell Communication Signaling"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0337","article-title":"Ly2109761, A Novel Transforming Growth Factor \u03b2 Receptor Type I and Type Ii Dual Inhibitor, as a Therapeutic Approach to Suppressing Pancreatic Cancer Metastasis","volume":"7","author":"Melisi","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.029025","article-title":"Inhibition of Transforming Growth Factor \u03b2 Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness","volume":"72","author":"Gaspar","year":"2007","journal-title":"Mol Pharmacol"},{"key":"B74","article-title":"Antitumor Activity of Tgf-\u03b2, Inhibitor is Dependent on the Microenvironment","volume":"27","author":"Medicherla","year":"2007","journal-title":"Anticancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0018","article-title":"Targeting Endogenous Transforming Growth Factor \u03b2 Receptor Signaling in Smad4-Deficient Human Pancreatic Carcinoma Cells Inhibits Their Invasive Phenotype 1","volume":"64","author":"Subramanian","year":"2004","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2895-4","article-title":"Phase 1 Study of Galunisertib, a Tgf-Beta Receptor I Kinase Inhibitor, in Japanese Patients With Advanced Solid Tumors","volume":"76","author":"Fujiwara","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.2174\/1566524014666140603115831","article-title":"Hypoxia Signaling and the Metastatic Phenotype","volume":"14","author":"Mujcic","year":"2014","journal-title":"Curr Mol Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nature04871","article-title":"Hypoxia Signalling in Cancer and Approaches to Enforce Tumour Regression","volume":"441","author":"Pouyss\u00e9gur","year":"2006","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1187","article-title":"Targeting Hif-1 for Cancer Therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","article-title":"Role of Vhl Gene Mutation in Human Cancer","volume":"22","author":"Kim","year":"2004","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting Hypoxic Tumor Microenvironment in Pancreatic Cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/HP.S52636","article-title":"The Impact of Hypoxia in Pancreatic Cancer Invasion and Metastasis","volume":"2","author":"Yuen","year":"2014","journal-title":"Hypoxia"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.12.005","article-title":"The Wnt Signaling Pathway in Cancer","volume":"99","author":"Duchartre","year":"2016","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3470","article-title":"The Complex World of Wnt Receptor Signalling","volume":"13","author":"Niehrs","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1424006","article-title":"Wnt Signaling: Is the Party in the Nucleus","volume":"20","author":"Willert","year":"2006","journal-title":"Genes Dev"},{"key":"B86","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.3390\/ijms20174242","article-title":"Wnt\/\u03b2-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance","volume":"20","author":"Ram Makena","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25284","article-title":"Control of Apoptosis in Treatment and Biology of Pancreatic Cancer","volume":"117","author":"Modi","year":"2016","journal-title":"J Cell Biochem"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt127","article-title":"The Notch Signaling Pathway as a Mediator of Tumor Survival","volume":"34","author":"Capaccione","year":"2013","journal-title":"Carcinogenesis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.1.5.159","article-title":"Notch Signaling in Cancer","volume":"1","author":"Allenspach","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.07.048","article-title":"Notch Signaling: An Emerging Therapeutic Target for Cancer Treatment","volume":"369","author":"Yuan","year":"2015","journal-title":"Cancer Lett"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.08.027","article-title":"Deadly Crosstalk: Notch Signaling at the Intersection of Emt and Cancer Stem Cells","volume":"341","author":"Espinoza","year":"2013","journal-title":"Cancer Lett"},{"key":"B92","first-page":"173","article-title":"Role of Notch Signaling Pathway in Pancreatic Cancer","volume":"7","author":"Gao","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2013.03.003","article-title":"Notch Signaling in Pancreatic Cancer: Oncogene or Tumor Suppressor","volume":"19","author":"Avila","year":"2013","journal-title":"Trends Mol Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/ng1099","article-title":"Notch1 Functions as a Tumor Suppressor in Mouse Skin","volume":"33","author":"Nicolas","year":"2003","journal-title":"Nat Genet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4645","article-title":"Notch1 Functions as a Tumor Suppressor in a Model of K-Ras\u2013Induced Pancreatic Ductal Adenocarcinoma","volume":"70","author":"Hanlon","year":"2010","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-862","article-title":"Epithelial Notch Signaling Is a Limiting Step for Pancreatic Carcinogenesis","volume":"14","author":"Thomas","year":"2014","journal-title":"BMC Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e85502","DOI":"10.1371\/journal.pone.0085502","article-title":"The Mek\/Erk Pathway Promotes Notch Signalling in Pancreatic Cancer Cells","volume":"8","author":"Tremblay","year":"2013","journal-title":"PloS One"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00309-X","article-title":"Preinvasive and Invasive Ductal Pancreatic Cancer and Its Early Detection in the Mouse","volume":"4","author":"Hingorani","year":"2003","journal-title":"Cancer Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00140-5","article-title":"Notch Mediates Tgf\u03b1-Induced Changes in Epithelial Differentiation During Pancreatic Tumorigenesis","volume":"3","author":"Miyamoto","year":"2003","journal-title":"Cancer Cell"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1470806","article-title":"Hedgehog\/ras Interactions Regulate Early Stages of Pancreatic Cancer","volume":"20","author":"di Magliano","year":"2006","journal-title":"Genes Dev"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.07.015","article-title":"Pten Constrains Centroacinar Cell Expansion and Malignant Transformation in the Pancreas","volume":"8","author":"Stanger","year":"2005","journal-title":"Cancer Cell"},{"key":"B102","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.09.004","article-title":"Mechanism of Action of Immunotherapy","volume":"41","author":"Disis","year":"2014","journal-title":"Semin Oncol (Elsevier)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/0284186031000518","article-title":"Oncolytic Herpes Viruses as a Potential Mechanism for Cancer Therapy","volume":"42","author":"Lou","year":"2003","journal-title":"Acta Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/B978-0-12-398342-8.00008-2","article-title":"8 Oncolytic Adenoviruses for Cancer Immunotherapy: Data From Mice, Hamsters, and Humans","volume":"115","author":"Cerullo","year":"2012","journal-title":"Adv Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, A New Oncolytic Virus Immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic Viruses: A New Class of Immunotherapy Drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B107","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China Approves World's First Oncolytic Virus Therapy for Cancer Treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J Nat Cancer Ins"},{"key":"B108","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jbior.2014.09.016","article-title":"Roles of Signaling Pathways in Drug Resistance, Cancer Initiating Cells and Cancer Progression and Metastasis","volume":"57","author":"McCubrey","year":"2015","journal-title":"Adv Biol Regul"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.790150","article-title":"Oncolytic Virotherapy: From Bench to Bedside","volume":"9","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003836","article-title":"From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy Against Cancer","volume":"10","author":"Ilkow","year":"2014","journal-title":"PloS Pathog"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1172\/JCI9871","article-title":"Reovirus as a Novel Oncolytic Agent","volume":"105","author":"Norman","year":"2000","journal-title":"J Clin Invest"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00609-0","article-title":"Modulating the Tumor Microenvironment via Oncolytic Virus and Pi3k Inhibition Synergistically Restores Immune Checkpoint Therapy Response in Pten-Deficient Glioblastoma","volume":"6","author":"Xing","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B113","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omto.2017.09.001","article-title":"Tgf-\u03b2 Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma","volume":"7","author":"Hutzen","year":"2017","journal-title":"Mol Therapy-Oncolytics"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2014.28","article-title":"Role of Mapk in Oncolytic Herpes Viral Therapy in Triple-Negative Breast Cancer","volume":"21","author":"Gholami","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0046627","article-title":"A Novel Anticancer Therapy That Simultaneously Targets Aberrant P53 and Notch Activities in Tumors","volume":"7","author":"Yao","year":"2012","journal-title":"Plos One"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2922","article-title":"Oncotropic H-1 Parvovirus Infection Degrades Hif-1\u03b1 Protein in Human Pancreatic Cancer Cells Independently of Vhl and Rack1","volume":"46","author":"Cho","year":"2015","journal-title":"Int J Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/cancers13133233","article-title":"Inhibition of Mir-222 by Oncolytic Adenovirus Encoded Mirna Sponges Promotes Viral Oncolysis and Elicits Antitumor Effects in Pancreatic Cancer Models","volume":"13","author":"Raimondi","year":"2021","journal-title":"Cancers"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2014.40","article-title":"Microrna-Mediated Multi-Tissue Detargeting of Oncolytic Measles Virus","volume":"21","author":"B\u00e4rtsch","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00849-14","article-title":"Permissiveness of Human Cancer Cells to Oncolytic Bovine Herpesvirus 1 Is Mediated in Part by Kras Activity","volume":"88","author":"Cuddington","year":"2014","journal-title":"J Virol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.07.003","article-title":"Coxsackievirus Type B3 Is a Potent Oncolytic Virus Against Kras-Mutant Lung Adenocarcinoma","volume":"14","author":"Deng","year":"2019","journal-title":"Mol Therapy-Oncolytics"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.02.017","article-title":"Transient Inhibition of Pi3k\u03b4 Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus","volume":"28","author":"Ferguson","year":"2020","journal-title":"Mol Ther"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30929","article-title":"Blockade of Transforming Growth Factor-\u03b2 Signaling Enhances Oncolytic Herpes Simplex Virus Efficacy in Patient-Derived Recurrent Glioblastoma Models","volume":"141","author":"Esaki","year":"2017","journal-title":"Int J Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/VAAT.S17832","article-title":"The Impact of Hypoxia on Oncolytic Virotherapy","volume":"3","author":"Sheng Guo","year":"2011","journal-title":"Virus Adaptation Treat"},{"key":"B124","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/01.sla.0000128308.36393.38","article-title":"Utilizing Tumor Hypoxia to Enhance Oncolytic Viral Therapy in Colorectal Metastases","volume":"239","author":"Reinblatt","year":"2004","journal-title":"Ann Surg"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2744","article-title":"Effective Treatment of Tumors With Strong \u03b2-Catenin\/T-Cell Factor Activity by Transcriptionally Targeted Oncolytic Herpes Simplex Virus Vector","volume":"66","author":"Kuroda","year":"2006","journal-title":"Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.07.041","article-title":"A Novel Oncolytic Adenovirus Targeting Wnt Signaling Effectively Inhibits Cancer-Stem Like Cell Growth via Metastasis, Apoptosis and Autophagy in Hcc Models","volume":"491","author":"Zhang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3420","article-title":"Oncolytic Hsv\u2013Infected Glioma Cells Activate Notch in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition","volume":"26","author":"Otani","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.98","article-title":"Mir-148a-and Mir-216a-Regulated Oncolytic Adenoviruses Targeting Pancreatic Tumors Attenuate Tissue Damage Without Perturbation of Mirna Activity","volume":"22","author":"Bofill-De Ros","year":"2014","journal-title":"Mol Ther"},{"key":"B129","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.18632\/oncotarget.3350","article-title":"Late-Phase Mirna-Controlled Oncolytic Adenovirus for Selective Killing of Cancer Cells","volume":"6","author":"Bofill-De Ros","year":"2015","journal-title":"Oncotarget"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22394","article-title":"Expression Profiling Identifies Microrna Signature in Pancreatic Cancer","volume":"120","author":"Lee","year":"2007","journal-title":"Int J Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.2174\/156652311796150363","article-title":"Advances And Future Challenges in Adenoviral Vector Pharmacology and Targeting","volume":"11","author":"Khare","year":"2011","journal-title":"Curr Gene Ther"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301398","article-title":"Safety and Feasibility of Injection With an E1b-55 Kda Gene-Deleted, Replication-Selective Adenovirus (Onyx-015) Into Primary Carcinomas of the Pancreas: A Phase I Trial","volume":"8","author":"Mulvihill","year":"2001","journal-title":"Gene Ther"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1679-3","article-title":"Gene-Mediated Cytotoxic Immunotherapy as Adjuvant to Surgery or Chemoradiation for Pancreatic Adenocarcinoma","volume":"64","author":"Aguilar","year":"2015","journal-title":"Cancer Immunol Immunotherapy"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2020.02.012","article-title":"Tolerability and Safety of Eus-Injected Adenovirus-Mediated Double-Suicide Gene Therapy With Chemotherapy in Locally Advanced Pancreatic Cancer: A Phase 1 Trial","volume":"92","author":"Lee","year":"2020","journal-title":"Gastrointestinal Endoscopy"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674400","article-title":"Oncolytic Adenovirus Coding for a Variant Interleukin 2 (Vil-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control","volume":"12","author":"Quixabeira","year":"2021","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0240","article-title":"Novel Group C Oncolytic Adenoviruses Carrying a Microrna Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo","volume":"21","author":"Doerner","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.7150\/thno.40902","article-title":"Oligopeptide-Modified Poly (Beta-Amino Ester) s-Coated Adnuparme1a: Boosting the Efficacy of Intravenously Administered Therapeutic Adenoviruses","volume":"10","author":"Brugada-Vil\u00e0","year":"2020","journal-title":"Theranostics"},{"key":"B138","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2019.04.040","article-title":"Systemic Administration of Human Mesenchymal Stromal Cells Infected With Polymer-Coated Oncolytic Adenovirus Induces Efficient Pancreatic Tumor Homing and Infiltration","volume":"305","author":"Na","year":"2019","journal-title":"J Controlled Release"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic Cancer Therapy With Combined Mesothelin-Redirected Chimeric Antigen Receptor T Cells and Cytokine-Armed Oncolytic Adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic Adenovirus Expressing Relaxin (Ydc002) Enhances Therapeutic Efficacy of Gemcitabine Against Pancreatic Cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.10.015","article-title":"Potent Antitumor Effect of Neurotensin Receptor Targeted Oncolytic Adenovirus Co-Expressing Decorin and Wnt Antagonist in an Orthotopic Pancreatic Tumor Model","volume":"220","author":"Na","year":"2015","journal-title":"J Controlled Release"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.016","article-title":"Bioselection Reveals Mir-99b and Mir-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer","volume":"27","author":"Rovira-Rigau","year":"2019","journal-title":"Mol Ther"},{"key":"B143","doi-asserted-by":"publisher","first-page":"18041","DOI":"10.18632\/oncotarget.24710","article-title":"Combination of Interferon Expressing Oncolytic Adenovirus With Chemotherapy and Radiation Is Highly Synergistic in Hamster Model of Pancreatic Cancer","volume":"9","author":"Salzwedel","year":"2018","journal-title":"Oncotarget"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0671","article-title":"The Novel Oncolytic Adenoviral Mutant Ad5-3\u03b4-A20t Retargeted to \u03b1v\u03b26 Integrins Efficiently Eliminates Pancreatic Cancer Cells","volume":"17","author":"Man","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.230","article-title":"Rgd-Modified Oncolytic Adenovirus-Harboring Shpkm2 Exhibits a Potent Cytotoxic Effect in Pancreatic Cancer via Autophagy Inhibition and Apoptosis Promotion","volume":"8","author":"Xu","year":"2017","journal-title":"Cell Death Dis"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6472","article-title":"Synergistic Antitumor Effects of Cdk Inhibitor Sns-032 and an Oncolytic Adenovirus Co-Expressing Trail and Smac in Pancreatic Cancer","volume":"15","author":"Ge","year":"2017","journal-title":"Mol Med Rep"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0526","article-title":"Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-Rgd and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma","volume":"16","author":"Dai","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"iii39","DOI":"10.1093\/neuonc\/nou208.61","article-title":"First-In-Human Phase I Clinical Trial of Oncolytic Delta-24-Rgd (Dnx-2401) With Biological Endpoints: Implications for Viro-Immunotherapy","volume":"16","author":"Lang","year":"2014","journal-title":"Neuro-Oncology"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-015-1208-z","article-title":"Survivin Silencing and Trail Expression Using Oncolytic Adenovirus Increase Anti-Tumorigenic Activity in Gemcitabine-Resistant Pancreatic Cancer Cells","volume":"21","author":"Han","year":"2016","journal-title":"Apoptosis"},{"key":"B150","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/gt.2015.45","article-title":"Safety and Antitumor Effect of Oncolytic and Helper-Dependent Adenoviruses Expressing Interleukin-12 Variants in a Hamster Pancreatic Cancer Model","volume":"22","author":"Poutou","year":"2015","journal-title":"Gene Ther"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2213","article-title":"Safety and Efficacy of Vcn-01, an Oncolytic Adenovirus Combining Fiber Hsg-Binding Domain Replacement With Rgd and Hyaluronidase Expression","volume":"21","author":"Rodr\u00edguez-Garc\u00eda","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4453-z","article-title":"A Phase I Clinical Trial of Eus-Guided Intratumoral Injection of the Oncolytic Virus, Hf10 for Unresectable Locally Advanced Pancreatic Cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz247.031","article-title":"Results From Phase I Study of the Oncolytic Viral Immunotherapy Agent Canerpaturev (C-Rev) in Combination With Gemcitabine Plus Nab-Paclitaxel as First-Line Treatment of Unresectable Pancreatic Cancer","volume":"30","author":"Hashimoto","year":"2019","journal-title":"Ann Oncol"},{"key":"B154","first-page":"599","article-title":"Phase I Dose-Escalation Clinical Trial of Hf10 Oncolytic Herpes Virus in 17 Japanese Patients With Advanced Cancer","volume":"61","author":"Kasuya","year":"2014","journal-title":"Hepato-Gastroenterology"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.2174\/156800907780058808","article-title":"Clinical Experiment of Mutant Herpes Simplex Virus Hf10 Therapy for Cancer","volume":"7","author":"Nakao","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"B156","article-title":"A Phase I\/Ii Trial of Intra-Tumoral Endoscopic Ultrasound Injection of Onyx-015 With Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700515","article-title":"Adenovirus Mediated Herpes Simplex Virus Thymidine Kinase Gene Therapy in Bt4c Rat Glioma Model","volume":"9","author":"Tyynel\u00e4","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"B158","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jso.24626","article-title":"Oncolytic Viral Therapy for Pancreatic Cancer","volume":"116","author":"Rahal","year":"2017","journal-title":"J Surg Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0309","article-title":"Enhanced Nectin-1 Expression and Herpes Oncolytic Sensitivity in Highly Migratory and Invasive Carcinoma","volume":"11","author":"Yu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2006.10.019","article-title":"Determination and Analysis of the Dna Sequence of Highly Attenuated Herpes Simplex Virus Type 1 Mutant Hf10, A Potential Oncolytic Virus","volume":"9","author":"Ushijima","year":"2007","journal-title":"Microbes Infection"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2005.05.007","article-title":"Hf10, an Attenuated Herpes Simplex Virus (Hsv) Type 1 Clone, Lacks Neuroinvasiveness and Protects Mice Against Lethal Challenge With Hsv Types 1 and 2","volume":"7","author":"Mori","year":"2005","journal-title":"Microbes Infection"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33550","article-title":"Oncolytic Herpes Simplex Virus Hf10 (Canerpaturev) Promotes Accumulation of Cd8+ Pd-1- Tumor-Infiltrating T Cells in Pd-L1-Enriched Tumor Microenvironment","volume":"149","author":"Eissa","year":"2021","journal-title":"Int J Cancer"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.10.027","article-title":"Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma","volume":"29","author":"Zhang","year":"2021","journal-title":"Mol Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"e003809","DOI":"10.1136\/jitc-2021-003809","article-title":"Cd40l-Armed Oncolytic Herpes Simplex Virus Suppresses Pancreatic Ductal Adenocarcinoma by Facilitating the Tumor Microenvironment Favorable to Cytotoxic T Cell Response in the Syngeneic Mouse Model","volume":"10","author":"Wang","year":"2022","journal-title":"J Immuno Ther Cancer"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00149","article-title":"Genomic Signature of the Natural Oncolytic Herpes Simplex Virus Hf10 and its Therapeutic Role in Preclinical and Clinical Trials","volume":"7","author":"Eissa","year":"2017","journal-title":"Front Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3329-3","article-title":"Combination Treatment of Human Pancreatic Cancer Xenograft Models With the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus Hf10","volume":"21","author":"Yamamura","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.072","article-title":"Targeted Oncolytic Herpes Simplex Virus Type 1 Eradicates Experimental Pancreatic Tumors","volume":"26","author":"Gayral","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B169","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.3748\/wjg.v19.i31.5138","article-title":"Preclinical Evaluation of Herpes Simplex Virus Armed With Granulocyte-Macrophage Colony-Stimulating Factor in Pancreatic Carcinoma","volume":"19","author":"Liu","year":"2013","journal-title":"World J Gastroenterology: WJG"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2012.97","article-title":"Concurrent Chemotherapy Inhibits Herpes Simplex Virus-1 Replication and Oncolysis","volume":"20","author":"Kulu","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2010.65","article-title":"A Phase I Dose-Escalation Clinical Trial of Intraoperative Direct Intratumoral Injection of Hf10 Oncolytic Virus in Non-Resectable Patients With Advanced Pancreatic Cancer","volume":"18","author":"Nakao","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0695","article-title":"Strategic Combinations: The Future of Oncolytic Virotherapy With Reovirus","volume":"15","author":"Zhao","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9279-8","article-title":"Intravenous Administration of Reolysinr, a Live Replication Competent Rna Virus Is Safe in Patients With Advanced Solid Tumors","volume":"28","author":"Gollamudi","year":"2010","journal-title":"Investigational New Drugs"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.259","article-title":"Reolysin Is a Novel Reovirus-Based Agent That Induces Endoplasmic Reticular Stress-Mediated Apoptosis in Pancreatic Cancer","volume":"4","author":"Carew","year":"2013","journal-title":"Cell Death Dis"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0063-9","article-title":"Arming Oncolytic Reovirus With Gm-Csf Gene to Enhance Immunity","volume":"26","author":"Kemp","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First Oncolytic Virus Approved for Melanoma Immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"OncoImmunology"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-Specific and Tri-Specific Antibodies-the Next Big Thing in Solid Tumor Therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol Med"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-44874-0","article-title":"Targeting Cldn18. 2 by Cd3 Bispecific and Adc Modalities for the Treatments of Gastric and Pancreatic Cancer","volume":"9","author":"Zhu","year":"2019","journal-title":"Sci Rep"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001191","article-title":"Preconditioning of the Tumor Microenvironment With Oncolytic Reovirus Converts Cd3-Bispecific Antibody Treatment Into Effective Immunotherapy","volume":"8","author":"Groeneveldt","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.66","article-title":"Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Mol Ther"},{"key":"B181","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/cancers10060160","article-title":"A Phase Ii Study of Pelareorep (Reolysinr) in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma","volume":"10","author":"Mahalingam","year":"2018","journal-title":"Cancers"},{"key":"B182","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in Combination With the Oncolytic Virus Pelareorep and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma: A Phase Ib Study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3604-y","article-title":"A non-Controlled, Single Arm, Open Label, Phase Ii Study of Intravenous and Intratumoral Administration of Parvoryx in Patients With Metastatic, Inoperable Pancreatic Cancer: Parvoryx02 Protocol","volume":"17","author":"Hajda","year":"2017","journal-title":"BMC Cancer"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1020","article-title":"Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","volume":"27","author":"Hajda","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3361","article-title":"P53mva Therapy in Patients With Refractory Gastrointestinal Malignancies Elevates P53-Specific Cd8+ T-Cell Responses","volume":"20","author":"Hardwick","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.194","article-title":"First-In-Man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity","volume":"23","author":"Zeh","year":"2015","journal-title":"Mol Ther"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.27.15974","article-title":"Vaccinia Virus B18r Gene Encodes a Type I Interferon-Binding Protein That Blocks Interferon \u03b1 Transmembrane Signaling","volume":"270","author":"Colamonici","year":"1995","journal-title":"J Biol Chem"},{"key":"B188","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1371\/journal.pmed.0040353","article-title":"Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus","volume":"4","author":"Kirn","year":"2007","journal-title":"PloS Med"},{"key":"B189","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/cells10050985","article-title":"Anti-Tumor Effects of Mapk-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed With Cd\/Uprt Against Pancreatic Ductal Adenocarcinoma in Mice","volume":"10","author":"Kurosaki","year":"2021","journal-title":"Cells"},{"key":"B190","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.omto.2021.12.016","article-title":"Oncolytic Vaccinia Virus Injected Intravenously Sensitizes Pancreatic Neuroendocrine Tumors and Metastases to Immune Checkpoint Blockade","volume":"24","author":"Inoue","year":"2022","journal-title":"Mol Therapy-Oncolytics"},{"key":"B191","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jitc-2020-001624","article-title":"A Systemically Deliverable Vaccinia Virus With Increased Capacity for Intertumoral and Intratumoral Spread Effectively Treats Pancreatic Cancer","volume":"9","author":"Marelli","year":"2021","journal-title":"J Immunother Cancer 9"},{"key":"B192","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4143\/crt.2019.161","article-title":"Characterization of Oncolytic Vaccinia Virus Harboring the Human Ifnb1 and Ces2 Transgenes","volume":"52","author":"Cho","year":"2020","journal-title":"Cancer Res Treatment: Off J Korean Cancer Assoc"},{"key":"B193","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3892\/or.2018.6817","article-title":"Gemcitabine Combined With an Engineered Oncolytic Vaccinia Virus Exhibits a Synergistic Suppressive Effect on the Tumor Growth of Pancreatic Cancer","volume":"41","author":"Chen","year":"2019","journal-title":"Oncol Rep"},{"key":"B194","doi-asserted-by":"publisher","first-page":"82728","DOI":"10.18632\/oncotarget.21095","article-title":"Ing4 Expressing Oncolytic Vaccinia Virus Promotes Anti-Tumor Efficiency and Synergizes With Gemcitabine in Pancreatic Cancer","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"B195","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.omto.2017.04.001","article-title":"Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus Glv-1h68 With Nab-Paclitaxel Plus Gemcitabine","volume":"6","author":"Binz","year":"2017","journal-title":"Mol Therapy-Oncolytics"},{"key":"B196","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/PPO.0b013e318278c4a6","article-title":"Inherited Pancreatic Cancer Syndromes","volume":"18","author":"Solomon","year":"2012","journal-title":"Cancer J (Sudbury Mass.)"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-11-79","article-title":"Growth Inhibition of Different Human Colorectal Cancer Xenografts After a Single Intravenous Injection of Oncolytic Vaccinia Virus Glv-1h68","volume":"11","author":"Ehrig","year":"2013","journal-title":"J Trans Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.11.007","article-title":"Oncolytic Vaccinia Virus in Combination With Radiation Shows Synergistic Antitumor Efficacy in Pancreatic Cancer","volume":"344","author":"Dai","year":"2014","journal-title":"Cancer Lett"},{"key":"B199","doi-asserted-by":"publisher","first-page":"16008","DOI":"10.1038\/mto.2016.8","article-title":"Molecular Network, Pathway, and Functional Analysis of Time-Dependent Gene Changes Associated With Pancreatic Cancer Susceptibility to Oncolytic Vaccinia Virotherapy","volume":"3","author":"Haddad","year":"2016","journal-title":"Mol Therapy-Oncolytics"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1038689","article-title":"New Role of Interleukin-10 in Enhancing the Antitumor Efficacy of Oncolytic Vaccinia Virus for Treatment of Pancreatic Cancer","volume":"4","author":"Chard","year":"2015","journal-title":"Oncoimmunology"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29068","article-title":"Gmcsf-Armed Vaccinia Virus Induces an Antitumor Immune Response","volume":"136","author":"Parviainen","year":"2015","journal-title":"Int J Cancer"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1073\/pnas.46.9.1256","article-title":"An Unidentified, Filtrable Agent Isolated From Transplanted Human Tumors","volume":"46","author":"Toolan","year":"1960","journal-title":"Proc Natl Acad Sci USA"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420030311","article-title":"Attempts to Isolate H-1 Virus From Spontaneous Human Abortions: A Negative Report","volume":"3","author":"Newman","year":"1970","journal-title":"Teratology"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2325","article-title":"Molecular Pathways: Rodent Parvoviruses\u2014Mechanisms of Oncolysis and Prospects for Clinical Cancer Treatment","volume":"18","author":"N\u00fcesch","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B205","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/v13061019","article-title":"Human Retrotran-Sposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1pv in Pancreatic Cancer","volume":"13","author":"Neulinger-Mu\u00f1oz","year":"2021","journal-title":"Viruses"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1088","article-title":"Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1pv","volume":"15","author":"Angelova","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03688-13","article-title":"Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1pv and Gemcitabine in Pancreatic Cancer","volume":"88","author":"Angelova","year":"2014","journal-title":"J Virol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201302796","article-title":"Synergistic Combination of Valproic Acid and Oncolytic Parvovirus H-1 Pv as a Potential Therapy Against Cervical and Pancreatic Carcinomas","volume":"5","author":"Li","year":"2013","journal-title":"EMBO Mol Med"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.12.10.17678","article-title":"Interferon \u03b3 Improves the Vaccination Potential of Oncolytic Parvovirus H-1pv for the Treatment of Peritoneal Carcinomatosis in Pancreatic Cancer","volume":"12","author":"Grekova","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1279-4","article-title":"Antitumoral Activity of Parvovirus-Mediated Il-2 and Mcp-3\/Ccl7 Delivery Into Human Pancreatic Cancer: Implication of Leucocyte Recruitment","volume":"61","author":"Dempe","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.10.1685","article-title":"Oncolytic Measles Viruses for Cancer Therapy","volume":"4","author":"Nakamura","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0602-z","article-title":"Demonstration of Anti-Tumor Activity of Oncolytic Measles Virus Strains in a Malignant Pleural Effusion Breast Cancer Model","volume":"122","author":"Iankov","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.5.2087-2096.2001","article-title":"Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry Through the Tumor-Associated Carcinoembryonic Antigen","volume":"75","author":"Hammond","year":"2001","journal-title":"J Virol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.04.015","article-title":"Microrna-Sensitive Oncolytic Measles Virus for Chemovirotherapy of Pancreatic Cancer","volume":"21","author":"Singh","year":"2021","journal-title":"Mol Therapy-Oncolytics"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10901","article-title":"Chemovirotherapy for Pancreatic Cancer: Gemcitabine Plus Oncolytic Measles Vaccine Virus","volume":"18","author":"May","year":"2019","journal-title":"Oncol Lett"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3675","article-title":"Novel Epivirotherapeutic Treatment of Pancreatic Cancer Combining the Oral Histone Deacetylase Inhibitor Resminostat With Oncolytic Measles Vaccine Virus","volume":"49","author":"Ellerhoff","year":"2016","journal-title":"Int J Oncol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13064","article-title":"Measles Virus Selectively Blind to Signaling Lymphocyte Activity Molecule Has Oncolytic Efficacy Against Nectin-4-Expressing Pancreatic Cancer Cells","volume":"107","author":"Awano","year":"2016","journal-title":"Cancer Sci"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2670","article-title":"Monitoring the Initial Delivery of an Oncolytic Measles Virus Encoding the Human Sodium Iodide Symporter to Solid Tumors Using Contrast-Enhanced Computed Tomography","volume":"14","author":"Penheiter","year":"2012","journal-title":"J Gene Med"},{"key":"B219","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/cancers13051171","article-title":"Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions","volume":"13","author":"Holbrook","year":"2021","journal-title":"Cancers"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1126\/science.1181766","article-title":"Cryo-Em Model of the Bullet-Shaped Vesicular Stomatitis Virus","volume":"327","author":"Ge","year":"2010","journal-title":"Science"},{"key":"B221","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.virusres.2013.06.003","article-title":"Understanding and Altering Cell Tropism of Vesicular Stomatitis Virus","volume":"176","author":"Hastie","year":"2013","journal-title":"Virus Res"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.08.007","article-title":"Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers","volume":"18","author":"Nagalo","year":"2020","journal-title":"Mol Therapy-Oncolytics"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01643-19","article-title":"Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses With Improved Replication in Virus-Resistant Pancreatic Cancer Cells","volume":"94","author":"Seegers","year":"2020","journal-title":"J Virol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00461-17","article-title":"Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus","volume":"91","author":"Felt","year":"2017","journal-title":"J Virol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.10.026","article-title":"Induction of Apoptosis in Pancreatic Cancer Cells by Vesicular Stomatitis Virus","volume":"474","author":"Felt","year":"2015","journal-title":"Virology"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.08.003","article-title":"Breaking Resistance of Pancreatic Cancer Cells to an Attenuated Vesicular Stomatitis Virus Through a Novel Activity of Ikk Inhibitor Tpca-1","volume":"485","author":"Cataldi","year":"2015","journal-title":"Virology"},{"key":"B227","doi-asserted-by":"publisher","first-page":"61601","DOI":"10.18632\/oncotarget.11202","article-title":"Novel Biomarkers of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus","volume":"7","author":"Hastie","year":"2016","journal-title":"Oncotarget"},{"key":"B228","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.omto.2021.11.019","article-title":"Acquired Chemoresistance can Lead to Increased Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus","volume":"24","author":"Goad","year":"2022","journal-title":"Mol Therapy-Oncolytics"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2013.10.032","article-title":"Molecular Determinants of Susceptibility to Oncolytic Vesicular Stomatitis Virus in Pancreatic Adenocarcinoma","volume":"187","author":"Blackham","year":"2014","journal-title":"J Surg Res"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01412-13","article-title":"Oncolytic Vesicular Stomatitis Virus in an Immunocompetent Model of Muc1-Positive or Muc1-Null Pancreatic Ductal Adenocarcinoma","volume":"87","author":"Hastie","year":"2013","journal-title":"J Virol"},{"key":"B231","article-title":"Newcastle Disease Virus as an Oncolytic Agent","volume":"130","author":"Ravindra","year":"2009","journal-title":"Indian J Med Res"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4804(92)90310-V","article-title":"Newcastle Disease Virus Selectively Kills Human Tumor Cells","volume":"52","author":"Reichard","year":"1992","journal-title":"J Surg Res"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J Virol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.507","article-title":"Rac1 is Required for Oncolytic Ndv Replication in Human Cancer Cells and Establishes a Link Between Tumorigenesis and Sensitivity to Oncolytic Virus","volume":"29","author":"Puhlmann","year":"2010","journal-title":"Oncogene"},{"key":"B235","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/cgt.2013.78","article-title":"Different Responses of Human Pancreatic Adenocarcinoma Cell Lines to Oncolytic Newcastle Disease Virus Infection","volume":"21","author":"Buijs","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31026","article-title":"Newcastle Disease Virus Mediates Pancreatic Tumor Rejection via Nk Cell Activation and Prevents Cancer Relapse by Prompting Adaptive Immunity","volume":"141","author":"Schwaiger","year":"2017","journal-title":"Int J Cancer"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3390\/v7062756","article-title":"Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma","volume":"7","author":"Buijs","year":"2015","journal-title":"Viruses"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.663787","article-title":"Integrated Analysis of Microarray and Rna-Seq Data for the Identification of Hub Genes and Networks Involved in the Pancreatic Cancer","volume":"12","author":"Nisar","year":"2021","journal-title":"Front Genet"},{"key":"B239","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A Review of Cancer Immunotherapy: From the Past, to the Present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"B240","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving Antitumor Efficacy via Combinatorial Regimens of Oncolytic Virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"key":"B241","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/sonc.2002.33078","article-title":"Cancer Immunotherapy: The Interferon-\u03b1 Experience","volume":"29","author":"Kirkwood","year":"2002","journal-title":"Semin Oncol (Elsevier)"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1013","article-title":"Expression of Ifn-\u03b2 Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of Mesothelioma","volume":"69","author":"Willmon","year":"2009","journal-title":"Cancer Res"},{"key":"B243","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-1426-2-11","article-title":"Current Status of Granulocyte\u2013Macrophage Colony Stimulating Factor in the Immunotherapy of Melanoma","volume":"2","author":"Kaufman","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral Oh2, an Oncolytic Herpes Simplex Virus 2, in Patients With Advanced Solid Tumors: A Multicenter, Phase I\/Ii Clinical Trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer 9"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in Cancer: From Biology to Therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B246","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/cells9020400","article-title":"Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy","volume":"9","author":"Nguyen","year":"2020","journal-title":"Cells"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.173","article-title":"Minimal Rb-Responsive E1a Promoter Modification to Attain Potency, Selectivity, and Transgene-Arming Capacity in Oncolytic Adenoviruses","volume":"18","author":"Rojas","year":"2010","journal-title":"Mol Ther"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.184","article-title":"Galv Expression Enhances the Therapeutic Efficacy of an Oncolytic Adenovirus by Inducing Cell Fusion and Enhancing Virus Distribution","volume":"19","author":"Guedan","year":"2012","journal-title":"Gene Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.875188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T10:53:18Z","timestamp":1653389598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.875188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":248,"alternative-id":["10.3389\/fonc.2022.875188"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.875188","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"article-number":"875188"}}